Home » Stocks » AGEN

Agenus Inc. (AGEN)

Stock Price: $3.58 USD -0.07 (-1.92%)
Updated November 23, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 680.73M
Revenue (ttm) 91.41M
Net Income (ttm) -173.57M
Shares Out 190.15M
EPS (ttm) -1.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $3.58
Previous Close $3.65
Change ($) -0.07
Change (%) -1.92%
Day's Open 3.70
Day's Range 3.56 - 3.73
Day's Volume 1,898,553
52-Week Range 1.82 - 5.63

More Stats

Market Cap 680.73M
Enterprise Value 603.34M
Earnings Date (est) Mar 18, 2021
Ex-Dividend Date n/a
Shares Outstanding 190.15M
Float 157.45M
EPS (basic) -1.09
EPS (diluted) -1.09
FCF / Share -0.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 23.73M
Short Ratio 14.85
Short % of Float 15.07%
Beta 2.10
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.45
PB Ratio n/a
Revenue 91.41M
Operating Income -105.53M
Net Income -173.57M
Free Cash Flow -138.97M
Net Cash 77.39M
Net Cash / Share 0.41
Gross Margin -20.01%
Operating Margin -115.45%
Profit Margin -189.90%
FCF Margin -152.04%
ROA -34.78%
ROE n/a
ROIC 270.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$8.00*
(123.46% upside)
Low
8.00
Current: $3.58
High
8.00
Target: 8.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue15036.7842.8822.5724.826.983.0515.962.763.36
Revenue Growth307.92%-14.21%89.95%-9.04%255.67%129.13%-80.92%479.17%-17.97%-
Gross Profit15036.7842.8822.5724.826.982.5115.292.763.24
Operating Income-64.33-125-107-106-74.00-36.62-24.98-6.74-19.09-21.75
Net Income-108-160-121-127-87.88-42.49-30.07-11.32-23.28-21.91
Shares Outstanding13511198.4287.0778.2159.7529.7723.6319.9016.11
Earnings Per Share-0.80-1.44-1.23-1.46-1.13-0.71-1.12-0.51-1.21-1.41
Operating Cash Flow-18.68-131-94.23-79.96-47.18-38.23-19.531.01-16.25-14.76
Capital Expenditures-4.66-3.59-3.00-12.52-3.59-2.82-0.81-0.10-0.03-0.08
Free Cash Flow-23.34-135-97.23-92.48-50.77-41.05-20.350.91-16.28-14.84
Cash & Equivalents61.8153.0560.1976.4417240.2227.3521.4710.7519.78
Total Debt23.3913.361631311146.038.8735.9232.9234.20
Net Cash / Debt38.4239.70-103-54.2557.2034.2018.49-14.45-22.18-14.41
Assets15513613815724274.5334.8429.0919.8130.91
Liabilities38731121419617251.5139.3246.6940.6445.61
Book Value-225-172-75.82-39.1370.7323.02-4.48-23.18-26.41-14.71
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Agenus Inc.
Country United States
Employees 328
CEO Garo H. Armen

Stock Information

Ticker Symbol AGEN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AGEN
IPO Date February 4, 2000

Description

Agenus, a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.